Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

You may be eligible if

• Patients must have:
• Pathologic (histologic or cytologic) confirmation of NSCLC
• Stage IIIB with malignant pleural effusion or Stage IV disease
• At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy
• ECOG performance status 0 or 1
• Adequate organ system function
• Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).
• Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)
• Patients must not have had:
• Brain metastasis
• Prior chemotherapy for NSCLC
• Prior platinum-based chemotherapy for any indication